1550-1551 / 2437
Best response to dabrafenib (independent review
)
* Missing patients (SD, n = 4; CR, n = 1 [patient recategorized as SD]; not evaluable, n = 1). ** Patients with no RP2D assigned dose.
a
Percentage change from baseline in sum of products will be of perpendicular diameter of target lesions.
b
Includes all patients
with measurable disease and ≥ 1 post-baseline evaluation.
c
Plot shows maximum reduction on study (2 patients with PD previously
had SD; 1 PD was due to a new lesion).